JNJ Stock Summary and Trading Ideas (Johnson & Johnson | NYSE:JNJ)

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Johnson & Johnson trades on the NYSE stock market under the symbol JNJ.

As of November 11, 2026, JNJ stock price declined to $280.41 with 4,921,734 million shares trading.

JNJ has a beta of -0.42, meaning it tends to be less sensitive to market movements. JNJ has a correlation of 0.05 to the broad based SPY ETF.

JNJ has a market cap of $675.23 billion. This is considered a Mega Cap stock.

Last quarter Johnson & Johnson reported $25 billion in Revenue and $2.59 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.06.

In the last 3 years, JNJ traded as high as $283.25 and as low as $140.68.

The top ETF exchange traded funds that JNJ belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.

JNJ has outperformed the market in the last year with a price return of +51.6% while the SPY ETF gained +12.6%. JNJ has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +7.6% and +4.3%, respectively, while the SPY returned -1.5% and -1.3%, respectively.

JNJ support price is $275.33 and resistance is $286.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JNJ shares will trade within this expected range on the day.